Pulse Biosciences (PLSE) Q2 FY26 earnings call

Pulse Biosciences reported a quarter of significant clinical and financial progress, highlighted by accelerated enrollment in its pivotal AFib catheter study and a bolstered balance sheet. The company is leveraging strong physician enthusiasm for its nsPFA technology, which demonstrates rapid procedure times and high efficacy in early data, while strategically expanding its Vybrance thyroid nodule program through key partnerships. Management remains focused on advancing regulatory approvals and preparing for commercialization, supported by a strong cash position.